Dr. Hai Mi joined Kleiner Perkins Caufield & Byers China as a partner in 2015 and focuses on the firm’s life sciences practice.
Prior to joining KPCB China, Dr. Mi was a partner DT Capital responsible for investment in life science, healthcare and other related fields. Dr. Mi was the venture partner of SB China Venture Capital (SBCVC) and his investment transactions include BGI, SyMap Medical and Precise Light. Dr. Mi was Senior Director of Strategic Planning and then Vice President of Corporate Communications at WuXi PharmaTech (NYSE: WX) in Shanghai where he played an important role in NYSE listing, investor relations, and the acquisition of AppTec in US. He also served on the board of Chemspec International (NYSE: CPC) as an independent board director and the chairman of audit committee, and he participated in the privatization of Chemspec. Earlier Dr. Mi was a research scientist at Pfizer in US.
Dr. Mi obtained a Ph.D. in organic chemistry from New York University, an MBA from The University of Chicago Booth School of Business, and a B.S. in material science from Fudan University in Shanghai.